MDT-AP-0747
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 41.04
- os_event
- false
- age_years
- 0.75
- sex
- F
- new_clusters
- S2
- umap1_2d
- -1.299255114
- umap2_2d
- -8.806414696
- umap1_3d
- -2.021559089
- umap2_3d
- -1.57891613
- umap3_3d
- 4.426212894
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.430
- ALLOGRAFT_REJECTION+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- KRAS_SIGNALING_DN+0.370
- PANCREAS_BETA_CELLS+0.370
- INFLAMMATORY_RESPONSE+0.340
- INTERFERON_GAMMA_RESPONSE+0.340
- COAGULATION+0.300
- KRAS_SIGNALING_UP+0.300
- BILE_ACID_METABOLISM+0.290
Top 10 suppressed
- DNA_REPAIR-0.470
- MYC_TARGETS_V2-0.460
- G2M_CHECKPOINT-0.430
- MITOTIC_SPINDLE-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.410
- E2F_TARGETS-0.380
- MTORC1_SIGNALING-0.370
- MYC_TARGETS_V1-0.370
- PROTEIN_SECRETION-0.370
- TGF_BETA_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2495 | Med | Medulloblastoma | 0.953 |
| 2 | MDT-AP-1215 | Med | Medulloblastoma | 0.936 |
| 3 | MDT-AP-0446 | Med | Medulloblastoma | 0.918 |
| 4 | SRR1330699 | GTEX | — | 0.917 |
| 5 | SRR601006 | GTEX | — | 0.917 |
| 6 | SRR1319539 | GTEX | — | 0.916 |
| 7 | ERR2208964 | — | — | 0.911 |
| 8 | SRR1374115 | GTEX | — | 0.910 |
| 9 | SRR607935 | GTEX | — | 0.910 |
| 10 | SRR8392886 | — | cohortA1 | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |